Aclarion, a healthcare technology company based in Jeffco, has announced a plan to repurchase up to $2.5 million of its common stock over the next 12 months. The Board of Directors approved this share repurchase program as part of the company’s capital allocation strategy.
The timing and amount of repurchases will depend on market conditions, share prices, and other factors, with Aclarion stating that the program may be paused or altered at any time. The company plans to finance the buyback using its existing cash reserves.
Aclarion’s CEO, Brent Ness, said, “This authorization underscores our commitment to disciplined capital allocation and our belief that Aclarion’s current valuation does not fully reflect the strength of our platform and long-term growth opportunity.”
The company reported having approximately $19 million in cash and cash equivalents as of March 31, 2026, which it believes is sufficient to support its operations through upcoming milestones, including the initial stage of a randomized trial.
Greg Gould, Chief Financial Officer, noted the program’s significance, stating, “Given our current capital position and expected operating needs, we believe a share repurchase program is an efficient and disciplined way to deploy capital while maintaining the financial flexibility necessary to execute on our strategic priorities.”
The announcement is noteworthy as it reflects Aclarion’s focus on enhancing shareholder value while continuing investments in its healthcare technology initiatives.
For more information, visit the primary source at GlobeNewswire.